You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

COVID-19: Obtenez les dernières mises à jour ou faites une autoévaluation.

Certaines de ces informations ou toutes, dans certains cas, n’apparaissent qu’en Anglais. Vous pouvez demander la version française

Lignes directrices et conseils
À propos des lignes directrices

The Use of Targeted Therapies in Patients with Inoperable Locally Advanced or Metastatic Renal Cell Cancer: Updated Guideline 2017

Version: 2 ID: 3-8-4 mai 2017
Type of Content: Guidelines & Advice, Clinical
Document Status: In-Review
Authors:
S. Hotte, J. Brown, C. Canil, U. Emmenegger, C. Walker-Dilks, E. Winquist, Genitourninary Disease Site Group

Guideline Objective

The primary objective of this report is to determine the optimal targeted therapies for locally advanced or metastatic renal cell cancer (mRCC). The secondary objective is to determine whether a combination of targeted agents is better than any single targeted agent.

Patient Population

Adult patients with inoperable locally advanced or mRCC.

Intended Guideline Users

Oncologists who treat patients with RCC.

Research Questions

What are the optimal targeted therapies for locally advanced or mRCC?

pdf download Summary (PDF) (78.97 Ko)
pdf download Full Report (PDF) (516.17 Ko)